Valtronic has sold two operating subsidiaries to Cicor Group
Cicor Group has acquired the US and Moroccan subsidiaries of Valtronic. Through this transaction, Valtronic’s shareholders have secured the long-term development and success of the two entities, while Cicor gains access to the US market and doubles its production capacity in Morocco.
Valtronic is a full-service electronic medical device contract manufacturer covering the entire product life cycle, from concept to final production. The company’s expertise spans simple printed circuit board assembly (PCBA) to complete box builds. Its products and services are based on two core pillars: high-precision manufacturing, including non-automatable processes, and specialized electronic solutions.
Cicor Group is a Swiss publicly listed international provider of advanced electronics manufacturing services and substrate solutions. As of 2024, the group comprises approimately 30 subsidiaries operating across two business segments: electronic manufacturing services (EMS) and advanced substrates (AS). Cicor develops, manufactures, assembles, tests and distributes flexible, rigid and rigid-flex printed circuit boards, substrates, hybrid circuits and printed electronics.
Oaklins’ team in Switzerland acted as the exclusive M&A advisor to Valtronic in this transaction.
Contáctese con el equipo de la transacción
Transacciones relacionadas
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Conozca másbioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Conozca másBanook, backed by Motion Equity, has acquired Fluidda
Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.
Conozca más